NCT07660224Not yet recruiting
The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Thalassemia
The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Beta-Thalassemia Major
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
Beta-thalassemia major is a chronic hereditary blood disorder that requires lifelong treatment, including regular blood transfusions and iron chelation therapy. Poor adherence to treatment remains a significant challenge and may lead to iron overload and related complications. Self-efficacy is an important factor influencing patients' ability to adhere to treatment recommendations. This study aims to evaluate the effect of nurse-delivered Motivational Interviewing (MI) on treatment adherence and self-efficacy among Omani adults with beta-thalassemia major. A pre-experimental one-group repeated-measures design will be used. Approximately 45 participants will be recruited from the Oman National Center for Hematology and Bone Marrow Transplantation and Royal Hospital in Muscat, Oman. Participants will receive three individualized MI sessions over a period of six to eight weeks. Treatment adherence and self-efficacy will be assessed at baseline, immediately after completion of the intervention, and at three-month follow-up. Secondary outcomes include serum ferritin level and frequency of thalassemia-related hospital admissions. The findings will provide evidence regarding the usefulness of motivational interviewing in improving adherence-related outcomes among adults with beta-thalassemia major.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 16 Jun 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 10 Aug 2027
- Lead sponsor
- Oman Ministry of Health
- Diseases
- Thalassaemia
- NCT number
- NCT07660224
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 1 Nov 2026 to the primary completion date, 10 Aug 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current hospitalization for an acute medical condition at the time of recruitment.
- Severe cognitive impairment or psychiatric illness that may affect participation.
Other
- Participation in another structured psychosocial or behavioral intervention program.
- Unable or unwilling to provide informed consent.
Who the study is looking for
- Adults aged 18 years and older.
- Diagnosed with transfusion-dependent beta-thalassemia major.
- Receiving iron chelation therapy for at least 6 months.
- Receiving regular follow-up at the participating study sites.
- Able to communicate in Arabic or English.
- Willing and able to provide informed consent.
- Able to attend the motivational interviewing sessions and complete study questionnaires.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.